Five PLEDGE studies now active and enrolling patients to evaluate the safety and efficacy of relamorelin (investigational drug) in people with diabetic gastroparesis

Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital will hold its annual Minds Matter Benefit Dinner on Friday, May 17 at 6 p.m. for an evening to honor and support individuals affected by brain and spinal tumors. This year's theme is "Darkness to Light" and includes iconic Chicago television news anchor Robin Robinson who will serve as the master of ceremonies for the black-tie benefit dinner.

Eisai Inc. presented the latest clinical results on FYCOMPA®(perampanel) CIII, at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, including analyses highlighting the health and economic benefits of FYCOMPA.

Newly identified subsets of cell types present in joint tissue in people with rheumatoid arthritis and how they interact may explain why only some people respond to existing medications, according to two studies by co-senior author Laura Donlin, PhD, Co-Director of the Derfner Foundation Precision Medicine Laboratory at Hospital for Special Surgery (HSS) and collaborating colleagues.

This week, the House of Representatives will vote on Rep. Ann Kuster’s (D-N.H.) Protecting Americans with Preexisting Conditions Act (HR 986).

Taking a pharmaceutical formulation of cannabidiol, a cannabis-based medicine, cut seizures nearly in half for children with a rare and severe type of epilepsy called Dravet syndrome, according to a phase 3 study released today that will be presented at the American Academy of Neurology's 71st Annual Meeting in Philadelphia, May 4 to 10, 2019. Dravet syndrome, which starts in infancy, can lead to intellectual disability and frequent, prolonged seizures.

Obesity is One of the Largest Drivers of Preventable Chronic Disease; LeanMD's 360 Degree Solution is Medically Supervised, Pharmaceutically Enhanced, and Features Advancements in Healthcare

Top-line Data Anticipated in the Fourth Quarter of 2019

Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients who are biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve.

Innovative product portfolio based on TELA Bio's proven technology platform advances the design of biologic-based materials for reconstructive surgery.

The Mesothelioma Compensation Center is incredibly passionate about making certain that a person who was exposed to asbestos at any type of nuclear power plant and now has mesothelioma or asbestos exposure lung cancer receives the very best possible financial compensation.

BD BACTEC™ Platelet Quality Control Media is cleared by the U.S. Food and Drug Administration and CE-IVD marked for platelet testing

Just approved for OTC use in the U.S. market, Tremotyx is now available in the U.S market after its successful launch in Germany.

Flash therapy preclinical results presented at AACR

Renown Health, northern Nevada's healthcare leader and Reno's only locally owned not-for-profit health system, and Genome Medical, a leading nationwide telegenomics technology and services company, today announced a partnership to bring genetic counseling and educational services to participants of the Healthy Nevada Project.

For Second Year, Company Will Serve as Kidney Walk National Presenting Sponsor

Results presented as oral presentation at 45th Annual Meeting of European Society for Blood and Marrow Transplantation

Loopback Analytics, a leading provider of data-driven solutions for hospital and health systems, announced today it has partnered with The University of VermontMedical Center to help advance the network's specialty and ambulatory pharmacy services.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the first patient has been successfully dosed in a Phase IIa clinical study of IBI306, a recombinant fully human anti-proprotein convertase substilisin/kexin type 9 (anti-PCSK9) monoclonal antibody, for the treatment of hypercholesterolemia.

VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations